Biotechnology

ImmVira announced its signing of Series C+ financing and negotiation with further investors for the round

SHENZHEN, China, Oct. 26, 2022 /PRNewswire/ -- ImmVira announced its successful signing of Series-C+ financing transaction documents with the first batch of investors recently. This round of financing was initiated by China Merchants China Direct Investments Limited with participation of Lifebay ...

2022-10-26 14:26 2026

Alwin Capital's New Dual-Currency Fund Closed and Exceeded Fundraising Target

BEIJING, Oct. 25, 2022 /PRNewswire/ -- Alwin Capital recently closed a new dual-currency fund, raising overUS$300 million, which exceeds their fundraising target. The RMB investors of this new dual-currency fund ...

2022-10-25 23:10 2104

SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines

* CEPI supports up to 40 mil. USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil. could be made available for late-stage development. * SK bioscience to secure new vaccines and establish pandemic response system * SK bioscience to enhance human healt...

2022-10-25 20:00 2263

Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 24, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment o...

2022-10-24 21:00 2682

WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities

* WuXi Biologics adds further capacity and capability for drug product fill & finish, providing global customers with end-to-end integrated solutions for diversified modalities, including mRNA-LNP HANGZHOU, China, Oct. 23, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading gl...

2022-10-24 08:30 2052

SK bioscience Appoints New Executives towards Global Business Growth

* Global experts continue to join SK bioscience, while its U.S. corporate entity is being established * Company plans to strategically invest in personnel, innovation & infrastructure to ensure global competitiveness SEOUL, South Korea, Oct. 21, 2022 /PRNewswire/ -- SK bioscience, a global in...

2022-10-21 20:00 2516

Official Ground-breaking Ceremony of Wuhan Synthetic Biology Innovation Center & CABIO R&D Center Investment Project

WUHAN, China, Oct. 20, 2022 /PRNewswire/ -- On October 19th, 2022, the investment project of the CABIO R&D Center officially commenced in Wuhan Optical Valley. Upon the basis of the said investment project, the ground-breaking ceremony of the "Wuhan Synthetic Biology Innovation Center" project, ...

2022-10-20 20:30 2014

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States

CAMBRIDGE, Mass., ROTTERDAM and SUZHOU, China, Oct. 20, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, it has successfully completed the dosing of first patient in the global phase I trial of B7H4x4-1BB bispecific antibody HBM7008 inthe United States. This study will eva...

2022-10-20 16:20 1762

BGI Australia Receives NATA Certification for Clinical Whole Exome Sequencing

BRISBANE, Australia, Oct. 20, 2022 /PRNewswire/ -- BGI Australia's lab has achieved accreditation from the National Association of Testing Authorities (NATA) to perform clinical Whole Exome Sequencing inAustralia, paving the way for the global life sciences company to provide clinical sequencing ...

2022-10-20 15:27 1589

AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

SUZHOU, China and ROCKVILLE, Md., Oct. 19, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it will release results from the Phase I fir...

2022-10-20 07:16 1451

SeekIn Presents New Data Supporting its Pan-cancer Early Detection Test at the Early Detection of Cancer Conference 2022

The large case-control study demonstrates that SeekInCare® has 68.0% sensitivity at 98.0% specificity in 27 different cancer types as a whole. In both retrospective and prospective studies, the solid performance of SeekInCare® puts it into best-in-class category of multi-cancer early detection (...

2022-10-19 20:30 1253

STANDIGM TO ATTEND BIO-EUROPE® 2022

Standigm will present AI-driven drug discovery technology at the conference CAMBRIDGE, England, Oct. 18, 2022 /PRNewswire/ -- Standigm , the workflow AI-driven drug discovery company, today announced that it will be represented at the 28th annual BIO-Europe

2022-10-19 01:50 1640

CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

SHANGHAI, Oct. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatthe National Medical Products Administration (NMPA) ofChina has a...

2022-10-18 20:50 2527

Zhiyi Biotech Received Clinical Approval from U.S. FDA for SK10 in Chemotherapy-induced Diarrhea

GUANGZHOU, China, Oct. 18, 2022 /PRNewswire/ -- Zhiyi Biotech announced that FDA has approved the Company's Investigational New Drug (IND) application to develop SK10 (InactivatedBacteroides fragilis) for the treatment of Chemotherapy-induced Diarrhea (CID) . The approval of this IND authorizes Z...

2022-10-18 20:35 1015

WeTrade Group Announces the Launch of Global Payment System WTPay and Development Plan of Health Business

BEIJING, Oct. 18, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), a global diversified "software as a service" ("SaaS") technology service provider which is committed to providing technical support and digital transformation tools for enterprises across differ...

2022-10-18 17:02 3002

ImmVira announced to launch the construction of Global R&D and Commercialization Base

SHENZHEN, China, Oct. 18, 2022 /PRNewswire/ -- On October 18, 2022, ImmVira launched the construction of its Global R&D and Commercialization Base in Suzhou Wuzhong Biomedical Industrial Park (Lifebay),China. The day before, ImmVira's "Shanghai Business and Clinical Center" officially opened on t...

2022-10-18 16:22 1175

EditForce Realizes RNA-editing Technology of "U-to-C"

FUKUOKA, Japan, Oct. 18, 2022 /PRNewswire/ -- EditForce, Inc. (hereinafter "EditForce"), headquartered inFukuoka, Japan, has realized the world's first RNA-editing technology that enables RNA-editing bases to be changed from "U" to "C," and demonstrated that this technology works even in human ce...

2022-10-18 14:00 1247

iNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesis

* The transposon technology development following the customized CRISPR/Cas system for bacteriophage * 2nd Generation technology of Robot Bacteriophage BOSTON and SEOUL, South Korea, Oct. 17, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com

2022-10-18 11:56 1486

InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022

NANJING, China, Oct. 17, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology companydedicated to developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label, phase Ib trial evaluating t...

2022-10-18 08:00 1144

Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia

Clinical trial assessing allogeneic, HLA-matched, donor-derived allogeneic CAR-T therapy SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Oct. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicat...

2022-10-17 20:05 1206
1 ... 68697071727374 ... 129

Week's Top Stories